Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04939311
NCT04939311WithdrawnPhase 1

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

Priscilla Hsue, MD1 site in 1 countryStarted: July 1, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Withdrawn
Sponsor
Locations
1
Primary Endpoint
Change in Target-to-background ratio (TBR)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
40 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Documented HIV infection
  • •On continuous antiretroviral therapy and virologically suppressed HIV infection for ≥12 weeks prior to study entry
  • •CD4 T-cell count > 350 cells/mm3
  • •Male or female between the ages ≥ 40 years of age to <≤75
  • •Documented cardiovascular disease (
  • •Prior myocardial infarction,
  • •History of percutaneous coronary intervention,
  • •History of coronary artery bypass graft OR
  • •Angiographic evidence of >50% stenosis in at least one coronary artery] OR 1 CVD risk factor (T2DM, current smoking, hypertension, dyslipidemia, hsCRP≥2mg/L, family history)
  • •TBR of >1.6 of the MDS of the carotid/aorta at baseline. This baseline arterial TBR cutoff excludes the rare individual that lacks appreciable arterial inflammation. It is notable that while 5-10% of uninfected individuals will have lower TBRs, it is rare that an HIV infected individual will fall below this range.
  • •Female subjects must either be of non-childbearing potential as defined by menopause with amenorrhea for >2 years, bilateral oophorectomy, or agree to use adequate contraception throughout the study and for at least one month following termination and have a negative pregnancy test at screening prior to the first dose of drug.
  • •Males must use at least one method of contraception throughout the study.

Exclusion Criteria

  • •Pregnant/nursing women
  • •Uncontrolled hypertension or diabetes requiring insulin
  • •AST/ALT or alkaline phosphatase >2x ULN
  • •Cancer within the last 5 years with exception of squamous cell carcinoma and basal cell carcinoma
  • •Nephrotic syndrome or eGFR <60 mL/min/1.73m2
  • •Cytopenias which include 1) WBC <3.5 x103/uL 2) Platelet <120 x103/uL 3) ANC <1.5 x103/uL, and absolute lymphocytes <0.8 x 103/uL
  • •Anemia as fined by <10 g/dL
  • •Evidence of tuberculosis infection at screening within 30 days prior to screening.
  • •Family history of long QT syndrome, using medication that prolongs QT internal, OR evidence of prolonged QT of >470 msec as evidenced by ECG
  • •Acute systemic infection within 30 days
  • •On additional immunosuppressant or immunomodulatory therapies

Arms & Interventions

VB-201

Experimental

One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

Intervention: VB-201 (Drug)

Placebo

Placebo Comparator

One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Change in Target-to-background ratio (TBR)

Time Frame: 1 year (Baseline and Week 52)

Change in Target-to-background ratio (TBR) from baseline to follow-up study at 52 weeks as assessed by Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT)

Secondary Outcomes

  • Change in high sensitivity C-reactive protein (hs-CRP) in mg/L(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in Interleukin-6 (IL-6) in pg/mL(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in soluble cluster of differentiation (sCD163) ng/mL(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in Lipoprotein (a) [Lp(a)] in mg/dL(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in ng/mL(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in D-Dimer (ng/mL)(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in Markers of Immune Activation(1 year (Change from baseline to week 24 and baseline to week 52))
  • Change in Monocyte Activation(1 year (Change from baseline to week 24 and baseline to week 52))

Investigators

Sponsor
Priscilla Hsue, MD
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Priscilla Hsue, MD

Chief of Cardiology

University of California, San Francisco

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome EventAcute Coronary Syndrome
NCT00552188Tallikut Pharmaceuticals, Inc.52
Completed
Phase 2
Study to Assess VB-201 in Patients With PsoriasisActive Plaque Psoriasis
NCT01001468Vascular Biogenics Ltd. operating as VBL Therapeutics185
Recruiting
Not Applicable
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up StudyAcute Coronary Syndromes
NCT06427694Cambridge University Hospitals NHS Foundation Trust60
Completed
Phase 2
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese DiabeticsType 2 Diabetes Mellitus
NCT00486291VIVUS LLC210
Withdrawn
Phase 2
A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known WellIschemic Stroke
NCT05764122Biogen